Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids.
In order to investigate the effectiveness of microporous cholestyramine in the pharmacological management of intra- and extrahepatic cholestasis, a double-blind placebo-controlled study was carried out in 10 patients. Microporous cholestyramine or placebo 3 g t.i.d. were given orally over a four-week period. The active drug resulted statistically superior to the placebo in reducing itching intensity (p less than 0.01) and serum bile acids (p less than 0.01). A positive linear relationship between itching and serum bile acids (p less than 0.01) was also demonstrated.
D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000097:blood*; D001651:Cholestasis, Extrahepatic / Q000097:blood / Q000188:drug therapy*; D002780:Cholestasis, Intrahepatic / Q000097:blood / Q000188:drug therapy*; D002792:Cholestyramine Resin / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004304:Dosage Forms; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011537:Pruritus
D001647:Bile Acids and Salts; D004304:Dosage Forms; D002792:Cholestyramine Resin